Page 152 - Read Online

Page 20 Spiliopoulou et al. Cancer Drug Resist 2024;7:2 https://dx.doi.org/10.20517/cdr.2023.46

+
+
Ccr8 by Cd4 Cd25 regulatory T cells. J Exp Med 2001;194:847-53. DOI PubMed PMC
+
+
48. Sugiyama D, Nishikawa H, Maeda Y, et al. Anti-CCR4 mAb selectively depletes effector-type FoxP3 CD4 regulatory T cells,
evoking antitumor immune responses in humans. Proc Natl Acad Sci U S A 2013;110:17945-50. DOI PubMed PMC
49. Sarkar T, Dhar S, Chakraborty D, et al. FOXP3/HAT1 axis controls Treg infiltration in the tumor microenvironment by inducing
CCR4 expression in breast cancer. Front Immunol 2022;13:740588. DOI PubMed PMC
+
50. Medof ME, Rieder SA, Shevach EM. Disabled C3ar1/C5ar1 signaling in Foxp3 T regulatory cells leads to TSDR demethylation and
long-term stability. J Immunol 2023;211:1359-66. DOI PubMed
51. Bayati F, Mohammadi M, Valadi M, Jamshidi S, Foma AM, Sharif-Paghaleh E. The therapeutic potential of regulatory T cells:
challenges and opportunities. Front Immunol 2020;11:585819. DOI PubMed PMC
52. Dennis KL, Blatner NR, Gounari F, Khazaie K. Current status of interleukin-10 and regulatory T-cells in cancer. Curr Opin Oncol
2013;25:637-45. DOI PubMed PMC
53. Hsu P, Santner-Nanan B, Hu M, et al. IL-10 potentiates differentiation of human induced regulatory T cells via STAT3 and Foxo1. J
Immunol 2015;195:3665-74. DOI
54. Konkel JE, Zhang D, Zanvit P, et al. Transforming growth factor-β signaling in regulatory T cells controls T helper-17 cells and
tissue-specific immune responses. Immunity 2017;46:660-74. DOI
55. Wan YY, Flavell RA. TGF-β and regulatory T cell in immunity and autoimmunity. J Clin Immunol 2008;28:647-59. DOI
PubMed PMC
+
56. Pyzik M, Piccirillo CA. TGF-β1 modulates Foxp3 expression and regulatory activity in distinct CD4 T cell subsets. J Leukoc Biol
2007;82:335-46. DOI PubMed
57. Chen W. TGF-β regulation of T cells. Annu Rev Immunol 2023;41:483-512. DOI PubMed
58. Jain N, Nguyen H, Chambers C, Kang J. Dual function of CTLA-4 in regulatory T cells and conventional T cells to prevent
multiorgan autoimmunity. Proc Natl Acad Sci U S A 2010;107:1524-8. DOI PubMed PMC
59. Ledford H, Else H, Warren M. Cancer immunologists scoop medicine Nobel prize. Nature 2018;562:20-1. DOI PubMed
60. Da M, Chen L, Enk A, Ring S, Mahnke K. The multifaceted actions of CD73 during development and suppressive actions of
regulatory T cells. Front Immunol 2022;13:914799. DOI PubMed PMC
61. Chen S, Fan J, Zhang M, et al. CD73 expression on effector T cells sustained by TGF-β facilitates tumor resistance to anti-4-1BB/
CD137 therapy. Nat Commun 2019;10:150. DOI PubMed PMC
62. Nelson BH. IL-2, regulatory T cells, and tolerance. J Immunol 2004;172:3983-8. DOI PubMed
+
63. Gasteiger G, Kastenmuller W. Foxp3 regulatory T-cells and IL-2: the moirai of T-cell fates? Front Immunol 2012;3:179. DOI
PubMed PMC
64. Xydia M, Rahbari R, Ruggiero E, et al. Common clonal origin of conventional T cells and induced regulatory T cells in breast cancer
patients. Nat Commun 2021;12:1119. DOI PubMed PMC
65. Fan MY, Low JS, Tanimine N, et al. Differential roles of IL-2 signaling in developing versus mature Tregs. Cell Rep 2018;25:1204-
13.e4. DOI PubMed PMC
66. Shapiro MR, Peters LD, Brown ME, et al. Insulin-like growth factor-1 synergizes with IL-2 to induce homeostatic proliferation of
regulatory T cells. J Immunol 2023;211:1108-22. DOI PubMed PMC
67. O’Rourke DM, Nasrallah MP, Desai A, et al. A single dose of peripherally infused EGFRvIII-directed CAR T cells mediates antigen
loss and induces adaptive resistance in patients with recurrent glioblastoma. Sci Transl Med 2017:9:eaaa0984. DOI PubMed PMC
68. Wang L, Oill AT, Blanchard M, et al. Expansion of endogenous T cells in CSF of pediatric CNS tumor patients undergoing
locoregional delivery of IL13Rα2-targeting CAR T cells: an interim analysis. Res Sq 2023;In Press. DOI
69. Wang H, Franco F, Tsui YC, et al. CD36-mediated metabolic adaptation supports regulatory T cell survival and function in tumors.
Nat Immunol 2020;21:298-308. DOI PubMed PMC
70. Stroukov W, Mastronicola D, Albany CJ, Catak Z, Lombardi G, Scottà C. OMIP-090: a 20-parameter flow cytometry panel for rapid
analysis of cell diversity and homing capacity in human conventional and regulatory T cells. Cytometry A 2023;103:362-7. DOI
PubMed
71. Santegoets SJAM, Dijkgraaf EM, Battaglia A, et al. Monitoring regulatory T cells in clinical samples: consensus on an essential marker
set and gating strategy for regulatory T cell analysis by flow cytometry. Cancer Immunol Immunother 2015;64:1271-86. DOI
PubMed PMC
72. Mason GM, Lowe K, Melchiotti R, et al. Phenotypic complexity of the human regulatory T cell compartment revealed by mass
cytometry. J Immunol 2015;195:2030-7. DOI
73. Barcenilla H, Pihl M, Sjögren F, Magnusson L, Casas R. Regulatory T-cell phenotyping using CyTOF. In: Ono M, editor. Regulatory
T-cells. New York: Springer US; 2023. pp. 231-42. DOI
74. Jaimes MC, Leipold M, Kraker G, Amir EA, Maecker H, Lannigan J. Full spectrum flow cytometry and mass cytometry: a 32-marker
panel comparison. Cytometry A 2022;101:942-59. DOI PubMed PMC
75. Di Giacomo AM, Santangelo F, Amato G et al. 139P - First-in-human (FIH), pharmacokinetic (PK) and pharmacodynamic (PD)
study of IOA-244, a phosphoinositide 3-kinase delta (PI3K-d) inhibitor, in patients with advanced metastatic mesothelioma, uveal
and cutaneous melanoma. 2021. Available from: https://www.ionctura.com/admin/resources/139pdi-giacomoioa244esmo-io-
2021final.pdf. [Last accessed on 11 Jan 2024].
76. Singh U, Cui Y, Dimaano N, et al. Analytical validation of quantitative immunohistochemical assays of tumor infiltrating lymphocyte